Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series
Autor: | Gaetano Giuffrida, Filomena Daniele, Sergio Siragusa, Valeria Calafiore, Rita Santoro, Maria Francesca Mansueto, Mariasanta Napolitano, F Gagliano |
---|---|
Přispěvatelé: | Santoro, Rita Carlotta, Giuffrida, Gaetano, Daniele, Filomena, Gagliano, Fabio, Mansueto, Maria Francesca, Calafiore, Valeria, Siragusa, Sergio, Napolitano, Mariasanta |
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent Hemophilia A Hemarthrosis Hemophilic arthropathy rFVIII Pharmacokinetic Prophylaxis Haemophilia A 030204 cardiovascular system & hematology Hemophilia A Recombinant factor viii 03 medical and health sciences Young Adult 0302 clinical medicine hemic and lymphatic diseases Internal medicine Medicine Humans Child Variable disease severity Aged Retrospective Studies Thrombotic risk Factor VIII business.industry Hematology Hemarthrosis Middle Aged medicine.disease Third generation Clinical Practice Treatment Outcome Concomitant business 030215 immunology |
Popis: | BAY 81-8973 is an unmodified, full-length third generation recombinant factor VIII (rFVIII) which offers a more favorable pharmacokinetic (PK) profile, compared to its predecessor sucrose-formulated rFVIII (rFVIII-FS). We here report on a retrospective case series of nine patients affected by hemophilia A (HA), with variable disease severity, bleeding phenotype and comorbidities, to underline our clinical practice on prophylaxis with a recently introduced standard hall-life recombinant Factor VIII. The current case series highlights how the current clinical management of hemophilia is able to personalize treatment in several specific conditions like concomitant illnesses with thrombotic risk and allergic reactions. |
Databáze: | OpenAIRE |
Externí odkaz: |